Next Article in Journal
Complexome Profiling: Assembly and Remodeling of Protein Complexes
Next Article in Special Issue
Redox and Nucleophilic Reactions of Naphthoquinones with Small Thiols and Their Effects on Oxidization of H2S to Inorganic and Organic Hydropolysulfides and Thiosulfate
Previous Article in Journal
Differential Serotonin Uptake Mechanisms at the Human Maternal–Fetal Interface
Previous Article in Special Issue
Donor Heart Preservation with Hydrogen Sulfide: A Systematic Review and Meta-Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 15
10.3390/ijms22157808
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Gasotransmitters for the Therapeutic Prevention of Hypertension and Kidney Disease

by
Chien-Ning Hsu
1,2 and
You-Lin Tain
3,4,*
1
Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan
2
School of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan
3
Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
4
Institute for Translational Research in Biomedicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, Kaohsiung 833, Taiwan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(15), 7808; https://doi.org/10.3390/ijms22157808
Submission received: 21 June 2021 / Revised: 19 July 2021 / Accepted: 20 July 2021 / Published: 21 July 2021
(This article belongs to the Special Issue Therapeutic Aspects of Gasotransmitters in Cardiovascular and Renal Disease 2.0)
Browse Figures
Versions Notes

Abstract

:
Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S), three major gasotransmitters, are involved in pleiotropic biofunctions. Research on their roles in hypertension and kidney disease has greatly expanded recently. The developing kidney can be programmed by various adverse in utero conditions by so-called renal programming, giving rise to hypertension and kidney disease in adulthood. Accordingly, early gasotransmitter-based interventions may have therapeutic potential to revoke programming processes, subsequently preventing hypertension and kidney disease of developmental origins. In this review, we describe the current knowledge of NO, CO, and H2S implicated in pregnancy, including in physiological and pathophysiological processes, highlighting their key roles in hypertension and kidney disease. We summarize current evidence of gasotransmitter-based interventions for prevention of hypertension and kidney disease in animal models. Continued study is required to assess the interplay among the gasotransmitters NO, CO, and H2S and renal programming, as well as a greater focus on further clinical translation.

1. Introduction

Gasotransmitters, such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S), are small gaseous molecules that penetrate membranes and play key roles in biology. Although these gases are toxic in excess, they are endogenously generated and exert specific biological functions at the physiological level [1,2,3]. A brief overview of their toxic and physiological levels is given in Table 1 [1,2,3]. Since it was identified as the endothelium-derived relaxing factor in the 1980s, NO has rapidly gained attention as one of the most important signaling molecules in the cardiovascular system [4]. A decade later, CO emerged as a gaseous vascular modulator of the cardiovascular system [5]. H2S, next to NO and CO, has emerged as a third gasotransmitter with key roles in the regulation of cardiovascular and other systems [6]. All three gases have a significant impact on human health and potential value as a therapeutic target [1,2,4].
Chronic kidney disease (CKD) and hypertension are major non-communicable diseases, which are the leading causes of global deaths. According to the WHO, one in five women and one in four men have hypertension worldwide [7]. An estimated ~10% of the global population has CKD [8]. Hypertension and CKD are closely associated with an overlapping and interlinked cause and effect relationship [9], such that hypertension can lead to CKD progression and CKD is the most common cause of secondary hypertension. Of note, hypertension as well as kidney disease can take their origins in early life, and when identified early, can be healed to prevent more associated disorders and serious complications.
During kidney development, various early-life adverse environmental conditions can lead to hypertension and kidney disease in adulthood [10]. The idea was recently named “Developmental Origins of Health and Disease” (DOHaD) [11]. Conversely, through shifting therapeutic approach from adulthood to early life, namely, reprogramming, we have the potential to revoke disease processes before disease becomes apparent [12,13].
The three gases and their roles in established kidney disease and hypertension have been extensively reviewed elsewhere [4,5,6,14,15,16,17]. However, evaluating their impacts on hypertension and kidney disease of developmental origins has not been sufficiently addressed [18,19]. The aim of this review is to discuss, within the limits of present knowledge, how the three gasotransmitters are implicated in the developmental programming of hypertension and kidney disease. In particular, the review focuses on the potential of gasotransmitters for therapeutic prevention against hypertension and kidney disease of developmental origins.
We searched the PubMed/MEDLINE databases for studies published in English using the following search terms: “gasotransmitter”, “kidney disease’, “developmental programming”, “DOHaD”, “nitric oxide”, “hydrogen sulfide”, “carbon monoxide”, “heme oxygenase”, “oxidative stress”, “nephron”, “nephrogenesis”, “mother”, “pregnancy”, “gestation”, “offspring”, “progeny”, “reprogramming”, and “hypertension”. We also used the reference lists of identified articles to find additional studies. The last search was made on 30 May 2021.

2. Implications of Gasotransmitters in Pregnancy

A variety of adverse conditions during pregnancy can affect fetal development resulting in hypertension and kidney disease in adult offspring, including maternal malnutrition, maternal exposure to environmental chemicals/toxins, maternal illnesses, medication uses in pregnancy, etc. [10,12,13,20,21,22]. Gasotransmitters play a crucial role in the regulation of maternal hemodynamics, placenta vascular development, embryogenesis, feto-placental vascular reactivity, and fetal development during pregnancy [23,24,25]. Abnormalities of gasotransmitter production and signaling in compromised pregnancy are linked to adverse pregnancy and fetal outcomes. A drawing schematic summarizing the enzymatic production of NO, CO, and H2S, and signaling pathways able to maintain normal pregnancy and fetal development are depicted in Figure 1. Each gasotransmitter is discussed in turn.

2.1. Nitric Oxide

NO plays a vital role in the regulation of feto-placental circulation, fetal development, and transfer of nutrients from mother to fetus in normal pregnancy [26]. NO can be produced by L-Arginine–nitric oxide synthase (NOS)-dependent or NOS-independent pathways. There are three NOSs, namely, neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS), which converts L-Arginine to L-Citrulline and generate NO (Figure 1). The NOS-independent pathway involves the reduction of nitrite to NO [27]. This nitrate–nitrite–NO pathway is considered as an alternative source of NO to the classical L-Arginine–NOS pathway. NO bioavailability mainly depends on intracellular L-Arginine concentrations [28]. There are two L-Arginine derivatives, asymmetric and symmetric dimethylarginine (ADMA and SDMA), which share common cationic amino acid transporters (CATs) with L-Arginine to move in and out of cells [29]. Both ADMA and SDMA can compete with L-arginine and inhibit NO production [29,30]. These two methylarginines are formed by a family of protein arginine methyltransferases (PRMTs) [29]. Dimethylarginine dimethylaminohydrolase-1 (DDAH-1) and -2 (DDAH-2) can metabolize ADMA to L-Citrulline and dimethylamine. In early pregnancy, the increase in NO and the concomitant reduction in ADMA assist hemodynamic adaptation and uterine relaxation, to avoid disturbed intrauterine growth of the fetus. Conversely, NO-induced relaxation of the uterus in late pregnancy can be antagonized by physiologically increased ADMA levels to aid in preparing the uterine muscle fibers for the higher contractile activity that is required for successful delivery [31]. NO regulates the relaxation of vascular smooth muscle cells primarily by driving soluble guanylyl cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP). Besides, NO-induced relaxation of human placental arteries is partly mediated through a direct effect on the large-conductance Ca2+-activated K+ channel (BKCa) [32].
Maternal plasma arginine levels were reduced in pregnancies complicated by intrauterine growth retardation (IUGR) [33]. Likewise, plasma arginine concentrations and placental eNOS abundance were decreased in women with preeclampsia [34]. Conversely, high ADMA levels in pregnant women are associated with preeclampsia [35], gestational diabetes mellitus [36], and fetal mortality [37]. Another line of evidence supporting NO deficiency in pregnancy attributed to adverse maternal and offspring outcome is from animal research. A previous report demonstrated that eNOS knockout pregnant mice displayed uteroplacental hypoxia, resulting in IUGR [38]. Additionally, adult rat offspring born of dams exposed to the L-NG-Nitro arginine methyl ester (L-NAME, a NOS inhibitor) in pregnancy developed hypertension, proteinuria, and kidney disease [39,40].

2.2. Carbon Monoxide

Like NO, CO is a diatomic low molecular weight gas with similar molecular size and structure [41]. However, CO is a relatively non-radical, chemically stable gas. CO is produced endogenously as a by-product of heme degradation catalyzed by the action of heme oxygenase-1 (HO-1) or -2 (HO-2) enzymes. The two known CO signaling mechanisms are the cGMP-dependent and -independent pathways (Figure 1). Classical CO signaling is similar to NO signaling: CO activates sGC to increase cGMP stimulation of protein kinase G (PKG), resulting in smooth muscle relaxation. Although CO and NO bind sGC with similar affinity, NO-sGC is approximately 25–50 times more active than CO-sGC [42]. Besides, CO can directly enhance the activity of BKCa in rat vascular smooth muscle cells through a cGMP-independent mechanism [24].
In pregnant women, low respiratory CO levels are associated with hypertension in pregnancy and preeclampsia [43]. CO has been shown to induce vasodilation of human placental resistance blood vessels via activation of sGC in vitro [44]. Additionally, deficiencies in HO-1 impair placenta development which have been associated with pregnancy disorders, such as recurrent miscarriages, IUGR, and preeclampsia [45].

2.3. Hydrogen Sulfide

Figure 1 illustrates major enzymes for H2S synthesis, including cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3MST) [6]. In the human placenta, these three enzymes are able to yield H2S [46]. CBS and CSE are cytosolic enzymes, but 3MST exists primarily in the mitochondria. Both CBS and CSE use L-Cysteine to generate H2S. In an alternative pathway, 3-mercaptopyruvate (3-MP), the substrate for 3MST to produce H2S, is provided by cysteine aminotransferase (CAT) and D-amino acid oxidase (DAO) [47]. In the peroxisome, D-Cysteine can be catabolized by DAO to generate H2S [17]. In addition to the enzymatic pathway, H2S can be produced via non-enzymatical pathway or by bacteria [48].
Uterine CBS and CSE levels increase during pregnancy and decrease during labor [24]. Like BKCa, uterine smooth muscle KATP channel is important for uterine quiescence [49,50]. In humans, H2S can mediate vasodilation via KATP channel to maintain feto-placental circulation [51]. During pregnancy, CBS and KATP levels increase in human uterine artery smooth muscle cells [52]. However, decreased maternal H2S level and placental CBS and CSE protein levels relate to preeclampsia [51,53,54].
Collectively, NO, CO, and H2S play crucial roles for normal pregnancy. Dysregulated gasotransmitter signaling has been linked to preeclampsia, IUGR, stillbirth, and preterm labor [24,25]. Although specific mechanisms mediating cellular and organismal changes in pregnancy due to gasotransmitters await further exploration, emerging evidences suggest their therapeutic potential for compromised pregnancy to improve maternal and fetal outcomes.

3. Implications of Gasotransmitters in Hypertension and Kidney Disease

3.1. Gasotransmitters and Hypertension

Several lines of evidence indicate that NO, CO, and H2S play key roles in the pathogenesis of hypertension. The first are observations on knockout mice lacking genes responsible for gasotransmitter synthesis. First, eNOS knockout mice displayed hypertension [55]. The importance of H2S-generating enzymes in hypertension has also been demonstrated using CSE, CBS, or 3MST knockout mice [47,56,57,58]. Another report showed male HO-2 knockout mice are prone to develop renovascular hypertension [59].
The second line of evidences report dysregulated gasotransmitter signaling pathways in human and experimental models of hypertension. Prior research has addressed impaired L-Arginine–ADMA–NO pathway in the development of hypertension [60]. Dysregulated HO-1–CO pathway was reported to induce vascular dysfunction and hypertension in various animal models [61]. Likewise, deficiencies in H2S-generating enzymes and/or activity in hypertension has been established in various animal models, including the NO-deficient rats [62], the Dahl salt-sensitive rats [63], the spontaneously hypertensive rat (SHR) [64], and the renovascular hypertensive model [65].
Third, several therapeutic strategies targeting different gasotransmitters have demonstrated to be significant promising for beneficial effects against hypertension in various animal models [60,61,66,67,68].

3.2. Gasotransmitters and Kidney Disease

The gasotransmitter generating enzymes iNOS, eNOS, nNOS, HO-1, HO-2, CSE, CBS, and 3MST were detected in kidney cells comprising podocytes, glomerular endothelial cells, tubular cells, and mesangial cells, but not all of them are constitutively expressed in every cell type [69,70]. For example, eNOS is expressed in the glomerular endothelial cells, peritubular capillaries, and vascular bundles, while nNOS is mainly detected in the tubular epithelial cells of the macula densa [70]. Of note, iNOS and HO-1 are not constitutively expressed in the kidney but only expressed under certain pathophysiological conditions like inflammation [70].
In the kidney, NO performs important signaling functions including the modulation of renal sympathetic neural activity, control of renal hemodynamics, regulation of pressure-natriuresis, blunting of tubuloglomerular feedback, and inhibition of tubular sodium reabsorption [70]. Accordingly, impaired NO signaling has been implicated in the pathogenesis of kidney diseases. As reviewed elsewhere [14,71], kidney injury is attributed to NO deficiency in a variety of CKD models, such as diabetic nephropathy, chronic glomerular nephritis, the 5/6 nephrectomy model, the aging kidney, the Zucker obese rat, chronic allograft nephropathy, etc.
The beneficial actions of CO in the kidney have also been recognized [15]. Inhibition of superoxide production, activation of sGC, stimulation of NO production, and stimulation of p38 mitogen-activated protein kinase (MAPK) pathway are all examples of the beneficial effects of CO in the kidney to protect the kidney [15]. Deficiency or inhibition of HO-1 in animal models worsens renal structure and function, while increased expression is protective [72]. So far, evidences from animal models indicate that several kidney diseases have been associated with impaired HO-1 or -2 system, including diabetic nephropathy [73], lupus nephritis [74], nephrotoxic nephritis [75], ischemia-reperfusion injury [76], obstructive nephropathy [77], and CKD [78].
H2S regulates basic physiologic mechanisms of the kidney such as sodium reabsorption, glomerular filtration, and renal homeostasis [17]. In some animal models of kidney disease, such as CKD [79], acute kidney injury [80], cisplatin nephropathy [81], obstructive nephropathy [82], and diabetic nephropathy [83], it can serve as an agent that ameliorates kidney injury.

3.3. Crosstalk between NO, CO, and H2S in the Kidney and BP Control

Although NO and H2S share the same sGC–cGMP pathway to elicit relaxation in kidney cells [16], they act at different levels, with NO increasing production of cGMP through stimulation of sGC and H2S inhibiting cGMP degradation [84]. In rats, inhibition of NO by L-NAME, causes hypertension that can be prevented by the administration of sodium hydrosulfide (NaHS, a H2S donor), which also rescues NO bioavailability [85]. These data support the notion that there exists a NO/H2S crosstalk in the control of blood pressure (BP).
One of the NO-based cellular signaling pathways is via protein S-nitrosylation, the covalent addition of NO moiety to the sulfur atom of cysteine residues [86]. S-nitrosylation of specific proteins has been shown to be protective against kidney injury [86]. As observed for NO, H2S also employs post-translational modifications, namely, S-sulfhydration [87]. Endogenous H2S physiologically S-sulfydrates proteins on the thiol group of cysteine residues (e.g., glutathione), leading to the formation of the –SSH moiety. These observations lead to a hypothesis that there might be competition between S-nitrosylation and S-sulfhydration for the same cysteine residues in proteins, thus allowing the two gasotransmitters to regulate each other [84].
CO could also target sGC and regulate NO-mediated vasodilatation [88], which was supported by a report showing that transgenic mice overexpressing cell-specific HO-1 exhibit hypertension coinciding with decreased cGMP production in response to NO [89]. Additionally, CO could interfere with NOS activity and reduce NO generation as a consequence, thereby limiting NO-mediated vasodilation [90]. Although much is known about the CO and NO signaling pathways in the kidney, we so far do not fully understand how these two gaseous signaling systems interact with each other.
Moreover, all three gasotransmitters are involved in activation of nuclear factor erythroid 2-related factor 2 (NRF2) (Figure 2). NRF2 is a major regulator of HO-1 transcription responding to oxidative stress [72]. Upon activation, the NRF2-HO-1 pathway protects chronic kidney disease progression related to reduction of oxidative stress, inhibition of transforming growth factor-β (TGF-β)-driven fibrosis, reduction of inflammation and apoptosis [91]. Under basal conditions, NRF2 levels are kept low through the interaction with Kelch-like ECH associated protein 1 (KEAP1). Upon binding, the NRF2-KEAP1 interaction stabilizes the complex allowing for ubiquitylation, and ultimately proteasomal degradation of NRF2 [91]. Of note, NO and H2S can activate NRF2 via S-nitrosylation and S-sulfhydration of KEAP1, respectively [92,93]. In addition to NRF2, NO can regulate other redox-regulatory transcription factors, like nuclear factor κB (NFκB) and hypoxia-inducible factor-1α (HIF-1α), via S-nitrosylation [92]. As NFκB mediates inflammation and HIF-1α induces HO-1 expression, NO can interact with the NRF2–HO-1–CO signaling pathway in many different ways to prevent CKD progression. NFκB can also be S-sulfhydrated by H2S [93]. These observations indicate crosstalk mechanisms between NO, CO, and H2S are important determinants for kidney disease (Figure 2).
Although the beneficial actions of gasotransmitters against established kidney disease and hypertension have been established, their roles in mediating programmed responses behind developmental origins remain unclear. For this reason, this review will next outline the potential early-life interventions targeting NO, CO, and H2S signaling that may pose new opportunities for the therapeutic protection of hypertension and kidney disease.

4. Developmental Origins of Hypertension and Kidney Disease

4.1. Animal Models of Gasotransmitter-Related Renal Programming

So far, little reliable information exists regarding the impact of gasotransmitters on the development of hypertension and kidney disease in humans. Animal models enable researchers to consider various adverse environmental conditions in developmental stages to determine underlying programming processes and long-term outcome in adult offspring.
The developing kidney is extremely vulnerable to the effects of adverse environmental events, resulting in renal programming and eventually functional alterations and structural changes [94]. As reviewed elsewhere [10,12,21,94,95], renal programming is the major determinant of hypertension and kidney disease of developmental origins. Animal models particularly have provided more direct insight into the association between NO, CO, H2S, and renal programming. The current review is solely restricted to early-life insults starting in pregnancy and lactation period with focusing on gasotransmitter-related renal programming. Table 2 illustrates a variety of adverse conditions during pregnancy and lactation which may affect kidney development, resulting in hypertension and adverse renal outcomes in adulthood [71,96,97,98,99,100,101,102,103,104,105,106,107,108].
As shown in Table 2, the most common phenotype of renal programming being studied is hypertension [71,96,97,98,99,100,101,102,103,104,105,106,107,108]. Reduced nephron number has been demonstrated in offspring rats born of dams with caloric restriction [96,97] or streptozotocin-induced diabetes [98].
Our previous study reported that ADMA (a reactive oxygen species (ROS) inducer and endogenous NOS inhibitor) impaired ureteric bud branching morphogenesis, consequently leading to decreases of nephron number [32]. Additionally, kidney injury was addressed in models of maternal caloric restriction [96,97] and streptozotocin-induced diabetes [98,106]. Renal function was not determined or unaltered in most models of renal programming. In one study, GFR was decreased in 20-week-old mice offspring born to dams developed streptozotocin-induced diabetes [106]. Our review implicates that various early-life insults are relevant to renal programming, including maternal nutritional imbalance [96,97,100,108], maternal illnesses [98,99,101,106], prenatal environmental chemical exposures [104,105], and medication use during pregnancy [102,103,104].
Most studies focused on gasotransmitter NO [71,96,97,98,99,100,101,102,103,104,105], followed by H2S [99,103,107,108] and CO [106]. Impaired ADMA–NO pathway was reported in several models of renal programming, including maternal caloric restriction [96,97], streptozotocin-induced diabetes [98], maternal suramin administration [99], high-fructose diet [100], maternal adenine-induced CKD [101], prenatal glucocorticoid exposure [71,102], prenatal dexamethasone plus high-fat diet [103], prenatal dexamethasone plus TCDD exposure [104], and combined bisphenol A and high-fat diet exposure [105].
However, there is only one report demonstrating HO-1 is involved in maternal diabetes-induced hypertension and kidney disease [106]. Moreover, reduced renal H2S-synthesing enzyme expression, decreased renal H2S releasing activity, and low plasma H2S level have been reported in various models of programmed hypertension [99,103,107,108].

4.2. Therapeutic Prevention of Gasotransmitters for Hypertension and Kidney Disease of Developmental Origins

Various early-life insults can cause similar renal phenotypes, implying the existence of common pathways behind renal programming that may contribute to hypertension and kidney disease of developmental origins. Although the pathogenetic mechanisms have not yet been fully disclosed, certain renal programming mechanisms have been documented, including but not limited to, oxidative stress, aberrant renin–angiotensin system (RAS), dysregulated nutrient sensing signals, epigenetic regulation, gut microbiota dysbiosis, and sex differences [10,12,13,18,20,21,22,109,110,111]. Of note, each of the three gas signaling molecules has approximately mutual relationships with the above-mentioned mechanisms.
With a greater understanding of mechanisms behind renal programming, implementation of interventions for therapeutic prevention of hypertension and kidney disease in later life is feasible. An important message is that whereas therapeutic interventions can be delivered at any disease stage, reprogramming is barely restricted to key periods during early development. Here, we summarize the knowledge available today regarding gasotransmitters used as reprogramming strategies for developmental hypertension and kidney disease in various animal models [39,40,96,98,99,102,103,104,108,112,113,114,115,116,117,118,119,120,121], all of which are documented in Table 3. This review is only limited to gasotransmitter-based interventions as reprogramming strategies applied during pregnancy and/or lactation which are critical periods for kidney development.
Evidence from the studies reviewed indicates that rats are the most commonly used animal models. Rats become sexually mature at 6 weeks. In adulthood, one rat month is comparable to three human years [122]. Accordingly, Table 3 lists the therapeutic effects determined in rats ranging from 12 weeks to 8 months of rat age, which allows calculations to extract data for the specific age group that can be translated to humans. Note that little information currently exists in regard to large animals used for studying the roles of gasotransmitters on hypertension and kidney disease of developmental origins.

4.3. Nitric Oxide

Several therapeutic interventions have been used to increase NO bioavailability, such as supplementation of NO substrate, NO donors, ADMA-lowering agents, and enhancement of the expression and/or activity of NOS [18]. Nevertheless, only some of them have been reported for therapeutic prevention of programmed kidney disease and hypertension (Table 3).
L-Arginine supplementation has been considered as a therapeutic approach to improve NO bioavailability in human diseases [123], whereas its benefits from human trials remain inconclusive [124]. Although perinatal arginine supplementation combined with antioxidants has been reported to protect adult offspring against hypertension in spontaneously hypertensive rats (SHRs) and Fawn-hooded hypertensive (FHH) rats [125,126], whether perinatal arginine supplementation alone is able to reprogram hypertension and kidney disease of developmental origins has not been elucidated yet.
Because L-Citrulline can be converted to L-Arginine and it can bypass hepatic metabolism, oral L-Citrulline supplementation has been used as an add-on therapy to increase L-Arginine concentrations, subsequently increasing NO production [127]. Table 3 illustrates several models have been used to examine the reprogramming effects of perinatal L-Citrulline supplementation, including maternal NG-nitro–L-arginine methyl ester (L-NAME) exposure [40], maternal caloric restriction [96], streptozotocin-induced diabetes [98], and prenatal dexamethasone exposure [102]. In addition, early supplementation with L-Citrulline in young SHRs prevents the transition from prehypertension to hypertension [112].
The use of NO donors is another way to increase NO. Two NO donors—pentaerythritol tetranitrate and molsidomine—have been reported to prevent the development of hypertension in SHRs and FFH rats, respectively [113,114] (Table 3). However, so far little information exists with regard to NO donors in programming models to prevent kidney disease of developmental origins. Currently, a specific ADMA-lowering agent remains inaccessible. However, many currently used drugs have been reported to lower ADMA levels and restore NO bioavailability in human and experimental studies [14,19,106]. Among them—rosuvastatin, telmisartan, glucagon-like peptide-1 receptor agonist, and epigallocatechin-3-gallate—can decrease PRMT-1 (ADMA-generating enzyme) expression to reduce ADMA levels. Furthermore, telmisartan, resveratrol, metformin, melatonin, atorvastatin, N-acetylcysteine (NAC), vitamin E, salvianolic acid A, oxymatrine, and rosuvastatin have been reported to reduce ADMA level via enhancing the activity and/or expression of DDAHs (ADMA-metabolizing enzymes) [14]. Table 3 shows only few ADMA-lowering agents have been examined in the developmental programming models to prevent hypertension, including NAC [103], resveratrol [104], melatonin [115], and aliskiren [116]. Moreover, in mother rats that received melinjo (Gnetum gnemon) seed extract during lactation the development of hypertension programmed by excessive fructose intake in their female offspring could be prevented by enhancing eNOS expression [117].

4.4. Carbon Monoxide

As opposed to NO, limited information is available about the CO-based interventions to study their roles on kidney disease and hypertension of developmental origins. Carbon monoxide releasing molecules (CORMs), a group of chemical compounds capable of controlled CO release directly in tissues or organs, have emerged as a therapeutic tool for human diseases [128]. However, none of them have been examined in kidney disease and hypertension of developmental origins.
In addition to CORMs, HO-1 or Nrf2 activators are potential CO-based modalities to activate the NRF2–HO-1–CO signaling pathway. Many natural compounds have shown to be effective activators of NRF2/HO-1 like resveratrol, curcumin, quercetin, anthocyanins, carnosic acid, epigallocatechin gallate, celastrol, isothiocyanates, garlic-derived organosulfur compounds, etc. [129]. Aside from natural activators, some synthetic NRF2 activators have been developed for clinical application like dimethyl fumarate (DMF), oltipraz, and ursodiol [130].
There is general lack of studies investigating NRF2/HO-1 activators for the prevention of kidney disease of developmental origins. As shown in Table 3, only one study reported that maternal DMF treatment protected adult progeny against hypertension in a maternal dexamethasone exposure and postnatal high-fat diet model [118]. Our previous study demonstrated resveratrol therapy during pregnancy and lactation protects adult offspring against bisphenol A-induced liver damage is associated with activation of NRF2 [131]. Nevertheless, the impact of early-life resveratrol supplementation on NRF2/HO-1/CO signaling pathway awaits further elucidation.

4.5. Hydrogen Sulfide

So far, available H2S-based modalities used for therapeutic protection of hypertension and kidney disease include H2S donors, precursors of H2S, and organosulfur compounds. Inorganic sulfide salts like sodium hydrosulfide (NaHS) are the most widely used H2S donors to evaluate the therapeutic potential of exogenous H2S [68]. NaHS has shown anti-hypertensive effects in several hypertensive models, including NO-deficient rats [62], Dahl salt-sensitive rats [63], and SHRs [132]. In line with established hypertensive models, Table 3 shows maternal NaHS therapy during pregnancy and lactation periods prevented hypertension in adult offspring born to dams with renovascular hypertension [119]. Nevertheless, other H2S donors have not yet been tested in terms of their reprogramming effects on hypertension and kidney disease of developmental origins.
Precursors of H2S include L-Cysteine, D-Cysteine, and NAC, a stable cysteine analog. Table 3 shows perinatal NAC therapy protects adult offspring against hypertension programmed by various early-life insults, such as maternal L-NAME exposure [39], maternal suramin administration [99], prenatal dexamethasone and postnatal high-fat diet [103], maternal hypertension [108], and maternal nicotine exposure [120,121]. Although D- or L-cysteine supplementation between four and six weeks of age has been found to protect high salt-treated SHRs against hypertension and kidney injury at 12 weeks old [133], their uses in pregnancy and lactation implicating programming hypertension and kidney disease has not been explored yet. Another report demonstrated that supplementing garlic oil in pregnancy and lactation prevented hypertension programmed by a high-fat diet, which coinciding with increased expression and activity of H2S-producing enzymes in offspring kidneys [107]. Organosulfur compounds derived from garlic are natural precursors of H2S [134].
Several clinically used medications have been shown to increase H2S concentrations, such as amlodipine, aspirin, carvediol, atorvastatin, digoxin, paracetamol, metformin, ramipril, testosterone, vitamin D, and 17β-estradiol [135]. Additionally, significant progress has been achieved in recent years on new H2S-releasing drugs. It would be interesting to see whether these H2S-releasing drugs would appear to be a practical approach to prevent hypertension and kidney disease from further clinical translation.
Collectively, these findings indicate the potential impact of gasotransmitter-based interventions for therapeutic prevention of programmed kidney disease and hypertension. While these studies have also raised concern, the protective mechanisms behind some gasotransmitter-based interventions are not limited to only one gasotransmitter. For example, resveratrol has properties to lower ADMA and activate NRF2; however, to what extent its reprogramming effects on kidney disease and hypertension can be attributed to NO or CO deserves further clarification. Accordingly, a better understanding of each gasotransmitter-dependent and -independent mechanisms responsible for the reprogramming effects of various gasotransmitter-based interventions is therefore highly warranted.

5. Conclusions and Future Perspectives

Current evidences suggest a potential therapeutic role of gasotransmitter-based interventions for prevention of programmed hypertension and kidney disease. Although many NO-, CO-, and H2S-based drugs have led to a significant progress in our understanding of established hypertension and kidney disease, attention must be paid to prevent (and not just to treat) these diseases; translation from animal models into clinical practice will be an additional challenge.
Of note, much of the preclinical work investigated the reprogramming actions of NO and H2S, and most of them focused on hypertension of developmental origins. Nevertheless, there is little reliable information about the reprogramming effects of CO-based intervention. Meanwhile, we are aware that almost no studies have taken a holistic approach to simultaneous determinations of NO, CO, and H2S signaling pathway in one experiment. In view of the complex interplay between these three gasotransmitters, the reprogramming effect responding to each gasotransmitter-based intervention, either individually or in combination, are incomplete and difficult to predict. Furthermore, more attention should be paid to decide the optimal dosage and duration of gasotransmitter-based intervention using the appropriate animal models prior to clinical translation.

Author Contributions

Conceptualization, C.-N.H. and Y.-L.T.; data curation, C.-N.H. and Y.-L.T.; funding acquisition, Y.-L.T.; project administration, C.-N.H. and Y.-L.T.; writing—original draft, C.-N.H. and Y.-L.T.; writing—review and editing, C.-N.H. and Y.-L.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Chang Gung Memorial Hospital, Kaohsiung, Taiwan, grants CORPG8K0121, CORPG8J0121, CORPG8L0121, CORPG8L0261, and CORPG8L0301.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data will be available upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kajimura, M.; Fukuda, R.; Bateman, R.M.; Yamamoto, T.; Suematsu, M. Interactions of multiple gas-transducing systems: Hallmarks and uncertainties of CO, NO, and H2S gas biology. Antioxid. Redox Signal. 2010, 13, 157–192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Polhemus, D.J.; Lefer, D.J. Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. Circ. Res. 2014, 114, 730–737. [Google Scholar] [CrossRef] [PubMed]
  3. NIOSH Pocket Guide to Chemical Hazards. 2020. Available online: https://www.cdc.gov/niosh/npg/ (accessed on 19 July 2021).
  4. Lancaster, J.R. Historical origins of the discovery of mammalian nitric oxide (nitrogen monoxide) production/physiology/pathophysiology. Biochem. Pharmacol. 2020, 176, 113793. [Google Scholar] [CrossRef] [PubMed]
  5. Durante, W. Carbon monoxide and bile pigments: Surprising mediators of vascular function. Vasc. Med. 2002, 7, 195–202. [Google Scholar] [CrossRef]
  6. Kimura, H. The physiological role of hydrogen sulfide and beyond. Nitric Oxide 2014, 41, 4–10. [Google Scholar] [CrossRef]
  7. World Health Organization. Hypertension. 2019. Available online: https://www.who.int/news-room/fact-sheets/detail/hypertension (accessed on 12 May 2021).
  8. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2095–2128. [Google Scholar] [CrossRef]
  9. Weir, M.R. Hypertension and the kidney: Perspectives on the relationship of kidney disease and cardiovascular disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 2045–2050. [Google Scholar] [CrossRef]
  10. Tain, Y.L.; Hsu, C.N. Developmental origins of chronic kidney disease: Should we focus on early life? Int. J. Mol. Sci. 2017, 18, 381. [Google Scholar] [CrossRef] [Green Version]
  11. Haugen, A.C.; Schug, T.T.; Collman, G.; Heindel, J.J. Evolution of DOHaD: The impact of environmental health sciences. J. Dev. Orig. Health Dis. 2015, 6, 55–64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Tain, Y.L.; Joles, J.A. Reprogramming: A preventive strategy in hypertension focusing on the kidney. Int. J. Mol. Sci. 2016, 17, 23. [Google Scholar] [CrossRef] [Green Version]
  13. Paauw, N.D.; van Rijn, B.B.; Lely, A.T.; Joles, J.A. Pregnancy as a critical window for blood pressure regulation in mother and child: Programming and reprogramming. Acta Physiol. 2017, 219, 241–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Baylis, C. Nitric oxide synthase derangements and hypertension in kidney disease. Curr. Opin. Nephrol. Hypertens. 2012, 21, 1–6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Csongradi, E.; Juncos, L.A.; Drummond, H.A.; Vera, T.; Stec, D.E. Role of carbon monoxide in kidney function: Is a little carbon monoxide good for the kidney? Curr. Pharm. Biotechnol. 2012, 13, 819–826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Feliers, D.; Lee, H.J.; Kasinath, B.S. Hydrogen sulfide in renal physiology and disease. Antioxid. Redox Signal. 2016, 25, 720–731. [Google Scholar] [CrossRef] [Green Version]
  17. Scammahorn, J.J.; Nguyen, I.T.N.; Bos, E.M.; Van Goor, H.; Joles, J.A. Fighting oxidative stress with sulfur: Hydrogen sulfide in the renal and cardiovascular systems. Antioxidants 2021, 10, 373. [Google Scholar] [CrossRef]
  18. Hsu, C.N.; Tain, Y.L. Regulation of nitric oxide production in the developmental programming of hypertension and kidney disease. Int. J. Mol. Sci. 2019, 20, 681. [Google Scholar] [CrossRef] [Green Version]
  19. Hsu, C.N.; Tain, Y.L. Preventing developmental origins of cardiovascular disease: Hydrogen sulfide as a potential target? Antioxidants 2021, 10, 247. [Google Scholar] [CrossRef]
  20. Chong, E.; Yosypiv, I.V. Developmental programming of hypertension and kidney disease. Int. J. Nephrol. 2012, 2012, 760580. [Google Scholar] [CrossRef] [Green Version]
  21. Paixão, A.D.; Alexander, B.T. How the kidney is impacted by the perinatal maternal environment to develop hypertension. Biol. Reprod. 2013, 89, 144. [Google Scholar] [CrossRef]
  22. Hsu, C.N.; Tain, Y.L. Animal models for DOHaD research: Focus on hypertension of developmental origins. Biomedicines 2021, 9, 623. [Google Scholar] [CrossRef]
  23. Holwerda, K.M.; Faas, M.M.; van Goor, H.; Lely, A.T. Gasotransmitters: A solution for the therapeutic dilemma in preeclampsia? Hypertension 2013, 62, 653–659. [Google Scholar] [CrossRef] [PubMed]
  24. Guerra, D.D.; Hurt, K.J. Gasotransmitters in pregnancy: From conception to uterine involution. Biol. Reprod. 2019, 101, 4–25. [Google Scholar] [CrossRef] [PubMed]
  25. Rengarajan, A.; Mauro, A.K.; Boeldt, D.S. Maternal disease and gasotransmitters. Nitric Oxide 2020, 96, 1–12. [Google Scholar] [CrossRef]
  26. Rosselli, M.; Keller, P.J.; Dubey, R.K. Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. Hum. Reprod. Update 1998, 4, 3–24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Lundberg, J.O.; Weitzberg, E.; Gladwin, M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 2008, 7, 156–167. [Google Scholar] [CrossRef]
  28. Chin-Dusting, J.P.; Willems, L.; Kaye, D.M. L-Arginine transporters in cardiovascular disease: A novel therapeutic target. Pharmacol. Ther. 2007, 116, 428–436. [Google Scholar] [CrossRef]
  29. Tain, Y.L.; Hsu, C.N. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins 2017, 9, 92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Leiper, J.; Vallance, P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 1999, 43, 542–548. [Google Scholar] [CrossRef] [Green Version]
  31. Hsu, C.N.; Tain, Y.L. Impact of arginine nutrition and metabolism during pregnancy on offspring outcomes. Nutrients 2019, 11, 1452. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Sand, A.; Andersson, E.; Fried, G. Nitric oxide donors mediate vasodilation in human placental arteries partly through a direct effect on potassium channels. Placenta 2006, 27, 181–190. [Google Scholar] [CrossRef] [PubMed]
  33. Bavoux, F.; Georges, P.; Bouy, M.; Leroy, B. Growth retardation and amino acids. Analysis of maternal plasma and amniotic fluid. J. Gynecol. Obstet. Biol. Reprod. 1977, 6, 931–940. [Google Scholar]
  34. Kim, Y.J.; Park, H.S.; Lee, H.Y.; Ha, E.H.; Suh, S.H.; Oh, S.K.; Yoo, H.S. Reduced L-arginine level and decreased placental eNOS activity in preeclampsia. Placenta 2006, 27, 438–444. [Google Scholar] [CrossRef]
  35. Pettersson, A.; Hedner, T.; Milsom, I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet. Gynecol. Scand. 1998, 77, 808–813. [Google Scholar] [PubMed]
  36. Leiva, A.; Fuenzalida, B.; Barros, E.; Sobrevia, B.; Salsoso, R.; Sáez, T.; Villalobos, R.; Silva, L.; Chiarello, I.; Toledo, F.; et al. Nitric oxide is a central common metabolite in vascular dysfunction associated with diseases of human pregnancy. Curr. Vasc. Pharmacol. 2016, 14, 237–259. [Google Scholar] [CrossRef] [PubMed]
  37. Abraham, A.J.M.; Bobby, Z.; Chaturvedula, L.; Vinayagam, V.; Syed, H.; Jacob, S.E. Utility of time of onset of hypertension, ADMA and TAS in predicting adverse neonatal outcome in hypertensive disorders of pregnancy. Fetal Pediatr. Pathol. 2019, 38, 460–476. [Google Scholar] [CrossRef] [PubMed]
  38. Kusinski, L.C.; Stanley, J.L.; Dilworth, M.R.; Hirt, C.J.; Andersson, I.J.; Renshall, L.J.; Baker, B.C.; Baker, P.N.; Sibley, C.P.; Wareing, M.; et al. eNOS knockout mouse as a model of fetal growth restriction with an impaired uterine artery function and placental transport phenotype. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 303, R86–R93. [Google Scholar] [CrossRef] [PubMed]
  39. Tain, Y.L.; Lee, C.T.; Chan, J.Y.; Hsu, C.N. Maternal melatonin or N-acetylcysteine therapy regulates hydrogen sulfide-generating pathway and renal transcriptome to prevent prenatal NG-Nitro-L-arginine-methyl ester (L-NAME)-induced fetal programming of hypertension in adult male offspring. Am. J. Obstet. Gynecol. 2016, 215, 636.e1–636.e72. [Google Scholar] [CrossRef]
  40. Tain, Y.L.; Huang, L.T.; Lee, C.T.; Chan, J.Y.; Hsu, C.N. Maternal citrulline supplementation prevents prenatal NG-nitro-l-arginine-methyl ester (L-NAME)-induced programmed hypertension in rats. Biol. Reprod. 2015, 92, 7. [Google Scholar] [CrossRef] [Green Version]
  41. Hartsfield, C.L. Cross talk between carbon monoxide and nitric oxide. Antioxid. Redox Signal. 2002, 4, 301–307. [Google Scholar] [CrossRef] [PubMed]
  42. Sharma, V.S.; Magde, D. Activation of soluble guanylate cyclase by carbon monoxide and nitric oxide: A mechanistic model. Methods 1999, 19, 494–505. [Google Scholar] [CrossRef]
  43. Kreiser, D.; Baum, M.; Seidman, D.S.; Fanaroff, A.; Shah, D.; Hendler, I.; Stevenson, D.K.; Schiff, E.; Druzin, M.L. End tidal carbon monoxide levels are lower in women with gestational hypertension and pre-eclampsia. J. Perinatol. 2004, 24, 213–217. [Google Scholar] [CrossRef] [Green Version]
  44. Bainbridge, S.A.; Farley, A.E.; McLaughlin, B.E.; Graham, C.H.; Marks, G.S.; Nakatsu, K.; Brien, J.F.; Smith, G.N. Carbon monoxide decreases perfusion pressure in isolated human placenta. Placenta 2002, 23, 563–569. [Google Scholar] [CrossRef]
  45. Zhao, H.; Wong, R.J.; Kalish, F.S.; Nayak, N.R.; Stevenson, D.K. Effect of heme oxygenase-1 deficiency on placental development. Placenta 2009, 30, 861–868. [Google Scholar] [CrossRef] [Green Version]
  46. Patel, P.; Vatish, M.; Heptinstall, J.; Wang, R.; Carson, R.J. The endogenous production of hydrogen sulphide in intrauterine tissues. Reprod. Biol. Endocrinol. 2009, 7, 10. [Google Scholar] [CrossRef] [Green Version]
  47. Shibuya, N.; Kimura, H. Production of hydrogen sulfide from d-cysteine and its therapeutic potential. Front. Endocrinol. 2013, 4, 87. [Google Scholar] [CrossRef] [Green Version]
  48. Linden, D.R. Hydrogen Sulfide Signaling in the Gastrointestinal Tract. Antioxid. Redox Signal. 2014, 20, 818–830. [Google Scholar] [CrossRef] [PubMed]
  49. Lorca, R.A.; Prabagaran, M.; England, S.K. Functional insights into modulation of BKCa channel activity to alter myometrial contractility. Front. Physiol. 2014, 5, 289. [Google Scholar] [CrossRef] [Green Version]
  50. Benkusky, N.A.; Fergus, D.J.; Zucchero, T.M.; England, S.K. Regulation of the Ca2+-sensitive domains of the maxi-K channel in the mouse myometrium during gestation. J. Biol. Chem. 2000, 275, 27712–27719. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Cindrova-Davies, T.; Herrera, E.A.; Niu, Y.; Kingdom, J.; Giussani, D.A.; Burton, G.J. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: Hydrogen sulfide as a placental vasodilator. Am. J. Pathol. 2013, 182, 1448–1458. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Sheibani, L.; Lechuga, T.J.; Zhang, H.; Hameed, A.; Wing, D.A.; Kumar, S.; Rosenfeld, C.R.; Chen, D.B. Augmented H2S production via cystathionine beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation. Biol. Reprod. 2017, 96, 664–672. [Google Scholar] [CrossRef]
  53. Wang, K.; Ahmad, S.; Cai, M.; Rennie, J.; Fujisawa, T.; Crispi, F.; Baily, J.; Miller, M.R.; Cudmore, M.; Hadoke, P.W.; et al. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. Circulation 2013, 127, 2514–2522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Holwerda, K.M.; Bos, E.M.; Rajakumar, A.; Ris-Stalpers, C.; vanPampus, M.G.; Timmer, A.; Erwich, J.J.; Faas, M.M.; van Goor, H.; Lely, A.T. Hydrogen sulfide producing enzymes in pregnancy and preeclampsia. Placenta 2012, 33, 518–521. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Huang, P.L.; Huang, Z.; Mashimo, H.; Bloch, K.D.; Moskowitz, M.A.; Bevan, J.A.; Fishman, M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995, 377, 239–242. [Google Scholar] [CrossRef] [PubMed]
  56. Yang, G.; Wu, L.; Jiang, B.; Yang, W.; Qi, J.; Cao, K.; Meng, Q.; Mustafa, A.K.; Mu, W.; Zhang, S.; et al. H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008, 322, 587–590. [Google Scholar] [CrossRef] [Green Version]
  57. Dayal, S.; Bottiglieri, T.; Arning, E.; Maeda, N.; Malinow, M.R.; Sigmund, C.D.; Heistad, D.D.; Faraci, F.M.; Lentz, S.R. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ. Res. 2001, 88, 1203–1209. [Google Scholar] [CrossRef] [Green Version]
  58. Mani, S.; Li, H.; Untereiner, A.; Wu, L.; Yang, G.; Austin, R.C.; Dickhout, J.G.; Lhoták, Š.; Meng, Q.H.; Wang, R. Decreased Endogenous Production of Hydrogen Sulfide Accelerates Atherosclerosis. Circulation 2013, 127, 2523–2534. [Google Scholar] [CrossRef] [Green Version]
  59. Stout, J.M.; Gousset, M.U.; Drummond, H.A.; Gray, W., 3rd; Pruett, B.E.; Stec, D.E. Sex-specific effects of heme oxygenase-2 deficiency on renovascular hypertension. J. Am. Soc. Hypertens. 2013, 7, 328–335. [Google Scholar] [CrossRef] [Green Version]
  60. Tain, Y.L.; Hsu, C.N. Targeting on asymmetric dimethylarginine-related nitric oxide-reactive oxygen species imbalance to reprogram the development of hypertension. Int. J. Mol. Sci. 2016, 17, 2020. [Google Scholar] [CrossRef] [Green Version]
  61. Durante, W. Targeting heme oxygenase-1 in vascular disease. Curr. Drug Targets 2010, 11, 1504–1516. [Google Scholar] [CrossRef] [Green Version]
  62. Jin, S.; Teng, X.; Xiao, L.; Xue, H.; Guo, Q.; Duan, X.; Chen, Y.; Wu, Y. Hydrogen sulfide ameliorated L-NAME-induced hypertensive heart disease by the Akt/eNOS/NO pathway. Exp. Biol. Med. (Maywood). 2017, 242, 1831–1841. [Google Scholar] [CrossRef]
  63. Huang, P.; Chen, S.; Wang, Y.; Liu, J.; Yao, Q.; Huang, Y.; Li, H.; Zhu, M.; Wang, S.; Li, L.; et al. Down-regulated CBS/H2S pathway is involved in high-salt-induced hypertension in Dahl rats. Nitric Oxide 2015, 46, 192–203. [Google Scholar] [CrossRef]
  64. Xiao, L.; Dong, J.-H.; Jing-Hui, D.; Xue, H.-M.; Guo, Q.; Teng, X.; Wu, Y.-M. Hydrogen sulfide improves endothelial dysfunction via downregulating BMP4/COX-2 pathway in rats with hypertension. Oxid. Med. Cell. Longev. 2016, 2016, 1–10. [Google Scholar] [CrossRef] [Green Version]
  65. Van Goor, H.; Born, J.C.V.D.; Hillebrands, J.-L.; Joles, J.A. Hydrogen sulfide in hypertension. Curr. Opin. Nephrol. Hypertens. 2016, 25, 107–113. [Google Scholar] [CrossRef]
  66. Paulo, M.; Costa, D.E.F.R.; Bonaventura, D.; Lunardi, C.N.; Bendhack, L.M. Nitric oxide donors as potential drugs for the treatment of vascular diseases due to endothelium dysfunction. Curr. Pharm. Des. 2020, 26, 3748–3759. [Google Scholar] [CrossRef] [PubMed]
  67. Ndisang, J.F.; Tabien, H.E.; Wang, R. Carbon monoxide and hypertension. J. Hypertens. 2004, 22, 1057–1074. [Google Scholar] [CrossRef] [PubMed]
  68. Wen, Y.-D.; Wang, H.; Zhu, Y.Z. The Drug developments of hydrogen sulfide on cardiovascular disease. Oxid. Med. Cell. Longev. 2018, 2018, 4010395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Beck, K.F.; Pfeilschifter, J. Gasotransmitter synthesis and signalling in the renal glomerulus. Implications for glomerular diseases. Cell. Signal. 2021, 77, 109823. [Google Scholar] [CrossRef] [PubMed]
  70. Kone, B.C. Nitric oxide synthesis in the kidney: Isoforms, biosynthesis, and functions in health. Semin. Nephrol. 2004, 24, 299–315. [Google Scholar] [CrossRef]
  71. Wilcox, C.S. Oxidative stress and nitric oxide deficiency in the kidney: A critical link to hypertension? Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289, R913–R935. [Google Scholar] [CrossRef] [PubMed]
  72. Lever, J.M.; Boddu, R.; George, J.F.; Agarwal, A. Heme Oxygenase-1 in Kidney Health and Disease. Antioxid. Redox Signal. 2016, 25, 165–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Ndisang, J.F.; Jadhav, A. Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: Role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis. Endocrinology 2014, 155, 215–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Mackern-Oberti, J.P.; Llanos, C.; Carreno, L.J.; Riquelme, S.A.; Jacobelli, S.H.; Anegon, I.; Kalergis, A.M. Carbon monoxide exposure improves immune function in lupus-prone mice. Immunology 2013, 140, 123–132. [Google Scholar] [CrossRef] [PubMed]
  75. Mosley, K.; Wembridge, D.E.; Cattell, V.; Cook, H.T. Heme oxygenase is induced in nephrotoxic nephritis and hemin, a stimulator of heme oxygenase synthesis, ameliorates disease. Kidney Int. 1998, 53, 672–678. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Ferenbach, D.A.; Ramdas, V.; Spencer, N.; Marson, L.; Anegon, I.; Hughes, J.; Kluth, D.C. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol. Ther. 2010, 18, 1706–1713. [Google Scholar] [CrossRef] [PubMed]
  77. Kie, J.H.; Kapturczak, M.H.; Traylor, A.; Agarwal, A.; Hill-Kapturczak, N. Heme oxygenase-1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis. J. Am. Soc. Nephrol. 2008, 19, 1681–1691. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Zager, R.A.; Johnson, A.C.; Becker, K. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and ‘‘end-stage’’ kidney disease. Am. J. Physiol. Renal Physiol. 2011, 301, F1334–F1345. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  79. Dugbartey, G.J. The smell of renal protection against chronic kidney disease: Hydrogen sulfide offers a potential stinky remedy. Pharm. Rep. 2018, 70, 196–205. [Google Scholar] [CrossRef] [PubMed]
  80. Chen, Y.; Jin, S.; Teng, X.; Hu, Z.; Zhang, Z.; Qiu, X.; Tian, D.; Wu, Y. Hydrogen sulfide attenuates LPS-induced acute kidney injury by inhibiting inflammation and oxidative stress. Oxid. Med. Cell. Longev. 2018, 2018, 6717212. [Google Scholar] [CrossRef] [Green Version]
  81. Cao, X.; Zhang, W.; Moore, P.K.; Bian, J. Protective smell of hydrogen sulfide and polysulfide in cisplatin-induced nephrotoxicity. Int. J. Mol. Sci. 2019, 20, 313. [Google Scholar] [CrossRef] [Green Version]
  82. Lin, S.; Visram, F.; Liu, W.; Haig, A.; Jiang, J.; Mok, A.; Lian, D.; Wood, M.E.; Torregrossa, R.; Whiteman, M.; et al. GYY4137, a slow-releasing hydrogen sulfide donor, ameliorates renal damage associated with chronic obstructive uropathy. J. Urol. 2016, 196, 1778–1787. [Google Scholar] [CrossRef] [Green Version]
  83. Xue, R.; Hao, D.D.; Sun, J.P.; Li, W.W.; Zhao, M.M.; Li, X.H.; Chen, Y.; Zhu, J.H.; Ding, Y.J.; Liu, J.; et al. Hydrogen sulfide treatment promotes glucose uptake by increasing insulin receptor sensitivity and ameliorates kidney lesions in type 2 diabetes. Antioxid. Redox Signal. 2013, 19, 5–23. [Google Scholar] [CrossRef] [Green Version]
  84. Cirino, G.; Vellecco, V.; Bucci, M. Nitric oxide and hydrogen sulfide: The gasotransmitter paradigm of the vascular system. Br. J. Pharmacol. 2017, 174, 4021–4031. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Zhong, G.; Chen, F.; Cheng, Y.; Tang, C.; Du, J. The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. J. Hypertens. 2003, 21, 1879–1885. [Google Scholar] [CrossRef] [PubMed]
  86. Zhou, H.L.; Zhang, R.; Anand, P.; Stomberski, C.T.; Qian, Z.; Hausladen, A.; Wang, L.; Rhee, E.P.; Parikh, S.M.; Karumanchi, S.A.; et al. Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury. Nature 2019, 565, 96–100. [Google Scholar] [CrossRef]
  87. Mustafa, A.K.; Gadalla, M.M.; Sen, N.; Kim, S.; Mu, W.; Gazi, S.K.; Barrow, R.K.; Yang, G.; Wang, R.; Snyder, S.H. H2S signals through protein S-sulfhydration. Sci. Signal. 2009, 2, ra72. [Google Scholar] [CrossRef] [Green Version]
  88. Stec, D.E.; Drummond, H.A.; Vera, T. Role of carbon monoxide in blood pressure regulation. Hypertension 2008, 51, 597–604. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Imai, T.; Morita, T.; Shindo, T.; Nagai, R.; Yazaki, Y.; Kurihara, H.; Suematsu, M.; Katayama, S. Vascular smooth muscle cell-directed overexpression of heme oxygenase-1 elevates blood pressure through attenuation of nitric oxide-induced vasodilation in mice. Circ. Res. 2001, 89, 55–62. [Google Scholar] [CrossRef] [Green Version]
  90. Thorup, C.; Jones, C.L.; Gross, S.S.; Moore, L.C.; Goligorsky, M.S. Carbon monoxide induces vasodilation and nitric oxide release but suppresses endothelial NOS. Am. J. Physiol. 1999, 277, F882–F889. [Google Scholar] [CrossRef]
  91. Uddin, M.J.; Kim, E.H.; Hannan, M.A.; Ha, H. Pharmacotherapy against oxidative stress in chronic kidney disease: Promising small molecule natural products targeting Nrf2-HO-1 signaling. Antioxidants 2021, 10, 258. [Google Scholar] [CrossRef] [PubMed]
  92. Fernando, V.; Zheng, X.; Walia, Y.; Sharma, V.; Letson, J.; Furuta, S. S-Nitrosylation: An emerging paradigm of redox signaling. Antioxidants 2019, 8, 404. [Google Scholar] [CrossRef] [Green Version]
  93. Iciek, M.; Kowalczyk-Pachel, D.; Bilska-Wilkosz, A.; Kwiecień, I.; Górny, M.; Włodek, L. S-sulfhydration as a cellular redox regulation. Biosci. Rep. 2015, 36, e00304. [Google Scholar] [CrossRef]
  94. Kett, M.M.; Denton, K.M. Renal programming: Cause for concern? Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300, R791–R803. [Google Scholar] [CrossRef]
  95. Nüsken, E.; Dötsch, J.; Weber, L.T.; Nüsken, K.D. Developmental programming of renal function and re-programming approaches. Front. Pediatr. 2018, 6, 36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Tain, Y.L.; Hsieh, C.S.; Lin, I.C.; Chen, C.C.; Sheen, J.M.; Huang, L.T. Effects of maternal L-citrulline supplementation on renal function and blood pressure in offspring exposed to maternal caloric restriction: The impact of nitric oxide pathway. Nitric Oxide 2010, 23, 34–41. [Google Scholar] [CrossRef] [PubMed]
  97. Tain, Y.L.; Huang, L.T.; Hsu, C.N.; Lee, C.T. Melatonin therapy prevents programmed hypertension and nitric oxide deficiency in offspring exposed to maternal caloric restriction. Oxid. Med. Cell. Longev. 2014, 2014, 283180. [Google Scholar] [CrossRef] [PubMed]
  98. Tain, Y.L.; Lee, W.C.; Hsu, C.N.; Lee, W.C.; Huang, L.T.; Lee, C.T.; Lin, C.Y. Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers. PLoS ONE 2013, 8, e55420. [Google Scholar] [CrossRef]
  99. Tain, Y.L.; Hsu, C.N.; Lee, C.T.; Lin, Y.J.; Tsai, C.C. N-Acetylcysteine prevents programmed hypertension in male rat offspring born to suramin-treated mothers. Biol. Reprod. 2016, 95, 8. [Google Scholar] [CrossRef]
  100. Tain, Y.L.; Lee, W.C.; Wu, K.L.H.; Leu, S.; Chan, J.Y.H. Targeting arachidonic acid pathway to prevent programmed hypertension in maternal fructose-fed male adult rat offspring. J. Nutr. Biochem. 2016, 38, 86–92. [Google Scholar] [CrossRef]
  101. Hsu, C.N.; Yang, H.W.; Hou, C.Y.; Chang-Chien, G.P.; Lin, S.; Tain, Y.L. Maternal adenine-induced chronic kidney disease programs hypertension in adult male rat offspring: Implications of nitric oxide and gut microbiome derived metabolites. Int. J. Mol. Sci. 2020, 21, 7237. [Google Scholar] [CrossRef]
  102. Tain, Y.L.; Sheen, J.M.; Chen, C.C.; Yu, H.R.; Tiao, M.M.; Kuo, H.C.; Huang, L.T. Maternal citrulline supplementation prevents prenatal dexamethasone-induced programmed hypertension. Free Radic. Res. 2014, 48, 580–586. [Google Scholar] [CrossRef]
  103. Tai, I.H.; Sheen, J.M.; Lin, Y.J.; Yu, H.R.; Tiao, M.M.; Chen, C.C.; Huang, L.T.; Tain, Y.L. Maternal N-acetylcysteine therapy regulates hydrogen sulfide-generating pathway and prevents programmed hypertension in male offspring exposed to prenatal dexamethasone and postnatal high-fat diet. Nitric Oxide 2016, 53, 6–12. [Google Scholar] [CrossRef] [PubMed]
  104. Hsu, C.N.; Lin, Y.J.; Lu, P.C.; Tain, Y.L. Maternal resveratrol therapy protects male rat offspring against programmed hypertension induced by TCDD and dexamethasone exposures: Is it relevant to aryl hydrocarbon receptor? Int. J. Mol. Sci. 2018, 19, 2459. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Hsu, C.N.; Lin, Y.J.; Tain, Y.L. Maternal exposure to bisphenol A combined with high-fat diet-induced programmed hypertension in adult male rat offspring: Effects of resveratrol. Int. J. Mol. Sci. 2019, 20, 4382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Gwathmey, T.M.; Shaltout, H.A.; Rose, J.C.; Diz, D.I.; Chappell, M.C. Glucocorticoid-induced fetal programming alters the functional complement of angiotensin receptor subtypes within the kidney. Hypertension 2011, 57, 620–626. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  107. Hsu, C.N.; Hou, C.Y.; Chang-Chien, G.P.; Lin, S.; Tain, Y.L. Maternal garlic oil supplementation prevents high-fat diet-induced hypertension in adult rat offspring: Implications of H2S-generating pathway in the gut and kidneys. Mol. Nutr. Food Res. 2021, 65, e2001116. [Google Scholar] [CrossRef] [PubMed]
  108. Hsu, C.-N.; Hou, C.-Y.; Chang-Chien, G.-P.; Lin, S.; Tain, Y.-L. Maternal N-Acetylcysteine Therapy Prevents Hypertension in Spontaneously Hypertensive Rat Offspring: Implications of Hydrogen Sulfide-Generating Pathway and Gut Microbiota. Antioxidants 2020, 9, 856. [Google Scholar] [CrossRef]
  109. Tain, Y.L.; Chan, S.H.H.; Chan, J.Y.H. Biochemical basis for pharmacological intervention as a reprogramming strategy against hypertension and kidney disease of developmental origin. Biochem. Pharmacol. 2018, 153, 82–90. [Google Scholar] [CrossRef]
  110. Tain, Y.L.; Hsu, C.N. Interplay between oxidative stress and nutrient sensing signaling in the developmental origins of cardiovascular disease. Int. J. Mol. Sci. 2017, 18, E841. [Google Scholar] [CrossRef]
  111. Hsu, C.N.; Tain, Y.L. Targeting the renin-angiotensin-aldosterone system to prevent hypertension and kidney disease of developmental origins. Int. J. Mol. Sci. 2021, 22, 2298. [Google Scholar] [CrossRef]
  112. Koeners, M.P.; van Faassen, E.E.; Wesseling, S.; Sain-van der Velden, M.; Koomans, H.A.; Braam, B.; Joles, J.A. Maternal supplementation with citrulline increases renal nitric oxide in young spontaneously hypertensive rats and has long-term antihypertensive effects. Hypertension 2007, 50, 1077–1084. [Google Scholar] [CrossRef] [Green Version]
  113. Wu, Z.; Siuda, D.; Xia, N.; Reifenberg, G.; Daiber, A.; Münzel, T.; Förstermann, U.; Li, H. Maternal treatment of spontaneously hypertensive rats with pentaerythritoltetranitrate reduces blood pressure in female offspring. Hypertension 2015, 65, 232–237. [Google Scholar] [CrossRef] [Green Version]
  114. Wesseling, S.; Essers, P.B.; Koeners, M.P.; Pereboom, T.C.; Braam, B.; van Faassen, E.E.; Macinnes, A.W.; Joles, J.A. Perinatal exogenous nitric oxide in fawn-hooded hypertensive rats reduces renal ribosomal biogenesis in early life. Front. Genet. 2011, 2, 52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Tain, Y.L.; Leu, S.; Lee, W.C.; Wu, K.L.H.; Chan, J.Y.H. Maternal melatonin therapy attenuated maternal high-fructose combined with post-weaning high-salt diets-induced hypertension in adult male rat offspring. Molecules 2018, 23, E886. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Hsu, C.N.; Lee, C.T.; Huang, L.T.; Tain, Y.L. Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction. J. Renin Angiotensin Aldosterone Syst. 2015, 16, 506–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Uson-Lopez, R.A.; Kataoka, S.; Mukai, Y.; Sato, S.; Kurasaki, M. Melinjo (Gnetum gnemon) Seed extract consumption during lactation improved vasodilation and attenuated the development of hypertension in female offspring of fructose-fed pregnant rats. Birth Defects Res. 2018, 110, 27–34. [Google Scholar] [CrossRef]
  118. Hsu, C.N.; Lin, Y.J.; Yu, H.R.; Lin, I.C.; Sheen, J.M.; Huang, L.T.; Tain, Y.L. Protection of male rat offspring against hypertension programmed by prenatal dexamethasone administration and postnatal high-fat diet with the Nrf2 activator dimethyl fumarate during pregnancy. Int. J. Mol. Sci. 2019, 20, 3957. [Google Scholar] [CrossRef] [Green Version]
  119. Guo, Q.; Feng, X.; Xue, H.; Jin, S.; Teng, X.; Duan, X.; Xiao, L.; Wu, Y. Parental renovascular hypertension-induced autonomic dysfunction in male offspring is improved by prenatal or postnatal treatment with hydrogen sulfide. Front. Physiol. 2019, 10, 1184. [Google Scholar] [CrossRef] [Green Version]
  120. Xiao, D.; Huang, X.; Li, Y.; Dasgupta, C.; Wang, L.; Zhang, L. Antenatal antioxidant prevents nicotine-mediated hypertensive response in rat adult offspring. Biol. Reprod. 2015, 93, 66. [Google Scholar] [CrossRef] [Green Version]
  121. Xiao, D.; Wang, L.; Huang, X.; Li, Y.; Dasgupta, C.; Zhang, L. Protective effect of antenatal antioxidant on nicotine-induced heart ischemia-sensitive phenotype in rat offspring. PLoS ONE 2016, 11, e0150557. [Google Scholar] [CrossRef]
  122. Sengupta, P. The laboratory rat: Relating its age with human’s. Int. J. Prev. Med. 2013, 4, 624–630. [Google Scholar]
  123. Luiking, Y.C.; Ten Have, G.A.M.; Wolfe, R.R.; Deutz, N.E.P. Arginine de novo and nitric oxide production in disease states. Am. J. Physiol. Endocrinol. Metab. 2012, 303, E1177–E1189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  124. Rodrigues-Krause, J.; Krause, M.; Rocha, I.M.G.D.; Umpierre, D.; Fayh, A.P.T. Association of l-arginine supplementation with markers of endothelial function in patients with cardiovascular or metabolic disorders: A systematic review and meta-analysis. Nutrients 2018, 11, 15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Racasan, S.; Braam, B.; van der Giezen, D.M.; Goldschmeding, R.; Boer, P.; Koomans, H.A.; Joles, J.A. Perinatal L-arginine and antioxidant supplements reduce adult blood pressure in spontaneously hypertensive rats. Hypertension 2004, 44, 83–88. [Google Scholar] [CrossRef] [Green Version]
  126. Koeners, M.P.; Braam, B.; van der Giezen, D.M.; Goldschmeding, R.; Joles, J.A. Perinatal micronutrient supplements ameliorate hypertension and proteinuria in adult fawn-hooded hypertensive rats. Am. J. Hypertens. 2010, 23, 802–808. [Google Scholar] [CrossRef]
  127. Cynober, L.; Moinard, C.; De Bandt, J.P. The 2009 ESPEN Sir David Cuthbertson. Citrulline: A new major signaling molecule or just another player in the pharmaconutrition game? Clin. Nutr. 2010, 29, 545–551. [Google Scholar] [CrossRef]
  128. Hopper, C.P.; Zambrana, P.N.; Goebel, U.; Wollborn, J. A brief history of carbon monoxide and its therapeutic origins. Nitric Oxide 2021, 111–112, 45–63. [Google Scholar] [CrossRef] [PubMed]
  129. Funes, S.C.; Rios, M.; Fernández-Fierro, A.; Covián, C.; Bueno, S.M.; Riedel, C.A.; Mackern-Oberti, J.P.; Kalergis, A.M. Naturally derived heme-oxygenase 1 inducers and their therapeutic application to immune-mediated diseases. Front. Immunol. 2020, 11, 1467. [Google Scholar] [CrossRef] [PubMed]
  130. Robledinos-Antón, N.; Fernández-Ginés, R.; Manda, G.; Cuadrado, A. Activators and inhibitors of NRF2: A review of their potential for clinical development. Oxid. Med. Cell. Longev. 2019, 2019, 9372182. [Google Scholar] [CrossRef]
  131. Liao, J.X.; Chen, Y.W.; Shih, M.K.; Tain, Y.L.; Yeh, Y.T.; Chiu, M.H.; Chang, S.K.C.; Hou, C.Y. Resveratrol butyrate esters inhibit bpa-induced liver damage in male offspring rats by modulating antioxidant capacity and gut microbiota. Int. J. Mol. Sci. 2021, 22, 5273. [Google Scholar] [CrossRef]
  132. Tain, Y.-L.; Hsu, C.-N.; Lu, P.-C. Early short-term treatment with exogenous hydrogen sulfide postpones the transition from prehypertension to hypertension in spontaneously hypertensive rat. Clin. Exp. Hypertens. 2017, 40, 58–64. [Google Scholar] [CrossRef]
  133. Hsu, C.N.; Lin, Y.J.; Lu, P.C.; Tain, Y.L. Early supplementation of D-cysteine or L-cysteine prevents hypertension and kidney damage in spontaneously hypertensive rats exposed to high-salt intake. Mol. Nutr. Food Res. 2018, 62, 2. [Google Scholar] [CrossRef] [PubMed]
  134. Zhu, Y.; Anand, R.; Geng, X.; Ding, Y. A mini review: Garlic extract and vascular diseases. Neurol. Res. 2018, 40, 421–425. [Google Scholar] [CrossRef] [PubMed]
  135. Bełtowski, J. Hydrogen sulfide in pharmacology and medicine—An update. Pharmacol. Rep. 2015, 67, 647–658. [Google Scholar] [CrossRef] [PubMed]
Ijms 22 07808 g001 550
Figure 1. Schematic illustration of the enzymatic synthesis of NO, CO, and H2S and downstream signaling able to maintain maternal and feto-placental homeostasis. NO (upper panel) is formed by neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS) from L-Arginine. Heme oxygenase-1 (HO-1) and -2 (HO-2) enzymes degrade heme to generate CO, iron, and biliverdin (middle panel). Three enzymes have been identified to enzymatically generate H2S (Lower panel), cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulphurtransferase (3MST). CBS and CSE produce H2S using L-cysteine. In an alternative pathway, 3-mercaptopyruvate (3-MP), the substrate for 3MST to produce H2S, is provided by cysteine aminotransferase (CAT) using L-Cysteine and D-amino acid oxidase (DAO) using D-Cysteine, respectively. The blue arrow lines indicate downstream signals of gasotransmitters in the maintenance of homeostasis in pregnancy. NO and CO both can activate soluble guanylate cyclase (sGC) to increase cGMP, resulting in smooth muscle relaxation. The large-conductance Ca2+-activated K+ channel (BKCa) can also be regulated by NO and CO to elicit vasodilatation. Additionally, through the activation of ATP-sensitive K+-channels (KATP), H2S can cause vasodilation in pregnancy.
Figure 1. Schematic illustration of the enzymatic synthesis of NO, CO, and H2S and downstream signaling able to maintain maternal and feto-placental homeostasis. NO (upper panel) is formed by neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS) from L-Arginine. Heme oxygenase-1 (HO-1) and -2 (HO-2) enzymes degrade heme to generate CO, iron, and biliverdin (middle panel). Three enzymes have been identified to enzymatically generate H2S (Lower panel), cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulphurtransferase (3MST). CBS and CSE produce H2S using L-cysteine. In an alternative pathway, 3-mercaptopyruvate (3-MP), the substrate for 3MST to produce H2S, is provided by cysteine aminotransferase (CAT) using L-Cysteine and D-amino acid oxidase (DAO) using D-Cysteine, respectively. The blue arrow lines indicate downstream signals of gasotransmitters in the maintenance of homeostasis in pregnancy. NO and CO both can activate soluble guanylate cyclase (sGC) to increase cGMP, resulting in smooth muscle relaxation. The large-conductance Ca2+-activated K+ channel (BKCa) can also be regulated by NO and CO to elicit vasodilatation. Additionally, through the activation of ATP-sensitive K+-channels (KATP), H2S can cause vasodilation in pregnancy.
Ijms 22 07808 g001
Ijms 22 07808 g002 550
Figure 2. Schematic illustration of the crosstalk among NO, CO, and H2S and downstream nuclear factor erythroid 2-related factor 2 (NRF2)–heme oxygenase-1 (HO-1) signaling able to protect chronic kidney disease progression. Activation of the NRF2–HO-1–CO signaling pathway suppresses nuclear factor κB (NFκB) and transforming growth factor-β (TGF-β), consequently inhibiting oxidative stress, inflammation, fibrosis, and apoptosis. NO and H2S can activate NRF2 via S-nitrosylation and S-sulfhydration of Kelch-like ECH associated protein 1 (KEAP1), respectively. Via S-nitrosylation, NO can also inhibit NFκB-induced inflammation and activate hypoxia-inducible factor-1α (HIF-1α), a HO-1 inducer. Additionally, NFκB can also be regulated by H2S via S-sulfhydration. NO and H2S also reduce TGFβ-mediated fibrosis.
Figure 2. Schematic illustration of the crosstalk among NO, CO, and H2S and downstream nuclear factor erythroid 2-related factor 2 (NRF2)–heme oxygenase-1 (HO-1) signaling able to protect chronic kidney disease progression. Activation of the NRF2–HO-1–CO signaling pathway suppresses nuclear factor κB (NFκB) and transforming growth factor-β (TGF-β), consequently inhibiting oxidative stress, inflammation, fibrosis, and apoptosis. NO and H2S can activate NRF2 via S-nitrosylation and S-sulfhydration of Kelch-like ECH associated protein 1 (KEAP1), respectively. Via S-nitrosylation, NO can also inhibit NFκB-induced inflammation and activate hypoxia-inducible factor-1α (HIF-1α), a HO-1 inducer. Additionally, NFκB can also be regulated by H2S via S-sulfhydration. NO and H2S also reduce TGFβ-mediated fibrosis.
Ijms 22 07808 g002
Table
Table 1. Physiological and toxic levels of NO, CO, and H2S.
Table 1. Physiological and toxic levels of NO, CO, and H2S.
Physiological LevelToxic Level
GasBlood ConcentrationExposure LimitIDLH
Nitric oxide (NO)Low nMTMA 25 ppm100 ppm
Carbon monoxide (CO)nM–μMTMA 35 ppm/C 200 ppm100 ppm
Hydrogen sulfide (H2S)High nM–low μMC 10 ppm1200 ppm
TWA = Time-weighted average; C = Ceiling; IDLH = Immediately dangerous to life or health concentrations; ppm = parts per million.
Table
Table 2. Summary of animal models of renal programming related to NO, CO, and H2S signaling.
Table 2. Summary of animal models of renal programming related to NO, CO, and H2S signaling.
Animal ModelsSpecies/
Gender		Age at EvaluationMechanisms Related to GasotransmitterRenal Outcome and Blood PressureRef.
Nitric oxide (NO)
Maternal caloric restriction dietSD rats/M12 weeks↑ ADMA
↓NO		Glomerular hypertrophy,
↑Tubulointerstitial injury and BP
↓Nephron number		[96,97]
Streptozotocin-induced diabetesSD rats/M12 weeks↑ADMA
↓NO		↑Tubulointerstitial injury and BP
↓Nephron number		[98]
Maternal suramin administrationSD rats/M12 weeks↑ADMA
↓NO		↑BP[99]
Maternal high-fructose dietSD rats/M12 weeks↓NO↑BP[100]
Maternal adenine-induced CKDSD rats/M12 weeks↑ADMA
↓NO		Renal hypertrophy
↑BP		[101]
Prenatal dexamethasone exposureSD rats/M16 weeks↓Renal NO↑BP[102]
Prenatal dexamethasone exposure plus postnatal high-fat intakeSD rats/M16 weeks↓NO↑BP[103]
Prenatal dexamethasone plus TCDD exposureSD rats/M16 weeks↑ADMA↑BP[104]
Prenatal bisphenol A exposure plus high-fat dietSD rats/M16 weeks↑ADMA
↓NO		↑BP[105]
Prenatal betamethasone exposureSheep/M and F18 months↓NO↑BP[71]
Carbon monoxide (CO)
Streptozotocin-induced diabetesHoxb7-GFP-Tg mice/M20 weeks↑Renal HO-1 expressionProteinuria, ↑Kidney injury, ↓GFR, ↑BP[106]
Hydrogen sulfide (H2S)
Maternal suramin administrationSD rats/M12 weeks↓Renal H2S releasing activity↑BP[99]
Maternal hypertensionSHRs/M12 weeks↓Renal 3MST protein expression & renal H2S releasing activity↑BP[107]
Prenatal dexamethasone exposure plus postnatal high-fat intakeSD rats/M16 weeks↓Renal CBS and 3MST protein expression↑BP[103]
Maternal and post-weaning high-fat dietSD rats/M16 weeks↓Plasma H2S level↑BP[108]
Studies tabulated according to types of gasotransmitters, species, and age at evaluation. TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin; CKD = Chronic kidney disease; ADMA = asymmetric dimethylarginine; SD = Sprague Dawley; SHR = spontaneously hypertensive rat; M = male; F = female; GFR = glomerular filtration rate; ↑ = increased; ↓ = decreased.
Table
Table 3. Summary of gasotransmitter-based interventions used for therapeutic prevention of hypertension and kidney disease of developmental origins.
Table 3. Summary of gasotransmitter-based interventions used for therapeutic prevention of hypertension and kidney disease of developmental origins.
Gasotransmitter-Based InterventionAnimal ModelsSpecies/
Gender		Age at EvaluationTherapeutic EffectsRef.
Nitric oxide (NO)
Substrate for NOS
0.25% L-Citrulline in drinking
water during pregnancy and lactation		Maternal L-NAME
exposure		SD rats/M12 weeksPrevented hypertension[40]
0.25% L-Citrulline in drinking
water during pregnancy and lactation		Maternal caloric restrictionSD rats/M12 weeksPrevented kidney
damage, increased
nephron number		[96]
0.25% L-Citrulline in drinking
water during pregnancy and lactation		Streptozotocin-induced diabetesSD rats/M12 weeksPrevented
hypertension and
kidney damage,
increased nephron
number		[98]
0.25% L-Citrulline in drinking
water during pregnancy and lactation		Prenatal dexamethasone exposureSD rats/M12 weeksPrevented
hypertension,
increased nephron
number		[102]
L-Citrulline (2.5 g/L) in drinking
water from 2 weeks before
until 6 weeks
after birth		Genetic hypertension modelSHR/M & F50 weeksPrevented
hypertension		[112]
NO donors
Pentaerythritol tetranitrate (50 mg/kg per day) during pregnancy and lactationGenetic hypertension modelSHR/M & F8 monthsPrevented
hypertension		[113]
Molsidomine (120 mg/L in drinking water) from 2 weeks before until 4 weeks
after birth		Genetic hypertension modelFHH/M & F42 weeksPrevented
hypertension		[114]
Asymmetric dimethylarginine (ADMA)-lowering agents
Resveratrol (50mg/L in drinking water) during pregnancy and lactationPrenatal dexamethasone plus TCDD exposureSD rats/M12 weeksPrevented
hypertension		[104]
Melatonin (0.01% in drinking water) during pregnancy and lactationMaternal
high-fructose diet
plus post-weaning
high-salt diet		SD rats/M12 weeksPrevented
hypertension		[115]
Aliskiren (10 mg/kg/day) from 2 weeks to 4 weeks after birthMaternal caloric restrictionSD rats/M12 weeksPrevented
hypertension		[116]
NAC (1% in drinking water) during pregnancy and lactationPrenatal dexamethasone exposure plus postnatal high-fat intakeSD rats/M16 weeksPrevented
hypertension		[103]
Enhancement of NOS
Melinjo (Gnetum gnemon) seed extract (1% in diet) from birth to postnatal week 3Maternal high-fructose dietWistar rats/F16 weeksPrevented
hypertension		[117]
Carbon monoxide(CO)
NRF2 activator
Daily oral gavage of dimethyl fumarate (50mg/kg/day) for 3 weeks during pregnancyPrenatal dexamethasone exposure plus postnatal high-fat intakeSD rats/M & F16 weeksPrevented hypertension[118]
Hydrogen sulfide (H2S)
H2S donors
Daily intraperitoneal injection of NaHS (56 μmol/kg/day) during pregnancy and lactation2-kidney, 1-clip renovascular hypertension modelSD rats/M & F16 weeksPrevented hypertension[119]
Precursors of H2S
NAC (1% in drinking water) during pregnancy and lactationMaternal L-NAME
exposure		SD rats/M12 weeksPrevented hypertension[39]
NAC (1% in drinking water) during pregnancy and lactationSuramin administrationSD rats/M12 weeksPrevented hypertension[99]
NAC (1% in drinking water) during pregnancy and lactationPrenatal
dexamethasone
and postnatal
high-fat diet		SD rats/M12 weeksPrevented hypertension[103]
NAC (1% in drinking water) during pregnancy and lactationMaternal hypertensionSHRs/M12 weeksPrevented hypertension[108]
NAC (500 mg/kg/day) in drinking water from gestational day 4 to postnatal day 10Maternal nicotine exposureSD rats/M8 monthsPrevented hypertension[120,121]
Organosulfur compounds
Daily oral gavage of garlic oil (100 mg/kg/day) during pregnancy and lactationMaternal and postweaning high-fat dietSD rats/M16 weeksPrevented hypertension[107]
Studies tabulated according to types of gasotransmitters and modalities, animal models and age at evaluation. L−NAME = NG-nitro-L-arginine-methyl ester. M = male. F = female. NAC = N-acetylcysteine. NaHS = sodium hydrosulfide. SHR = spontaneously hypertensive rat. SD = Sprague−Dawley rat. FHH = Fawn hooded hypertensive rat.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hsu, C.-N.; Tain, Y.-L. Gasotransmitters for the Therapeutic Prevention of Hypertension and Kidney Disease. Int. J. Mol. Sci. 2021, 22, 7808. https://doi.org/10.3390/ijms22157808

AMA Style

Hsu C-N, Tain Y-L. Gasotransmitters for the Therapeutic Prevention of Hypertension and Kidney Disease. International Journal of Molecular Sciences. 2021; 22(15):7808. https://doi.org/10.3390/ijms22157808

Chicago/Turabian Style

Hsu, Chien-Ning, and You-Lin Tain. 2021. "Gasotransmitters for the Therapeutic Prevention of Hypertension and Kidney Disease" International Journal of Molecular Sciences 22, no. 15: 7808. https://doi.org/10.3390/ijms22157808

APA Style

Hsu, C. -N., & Tain, Y. -L. (2021). Gasotransmitters for the Therapeutic Prevention of Hypertension and Kidney Disease. International Journal of Molecular Sciences, 22(15), 7808. https://doi.org/10.3390/ijms22157808

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop